- $2.05bn
- $1.53bn
- $6.94m
Brief: Immunome Reports Fourth Quarter And Full Year 2022 Financial Results
Brief: Immunome Announces Formation Of Antibody-Drug Conjugate And T Cell Redirection Advisory Board
Immunome up on pact with AbbVie to discover multiple oncology targets
Brief: Immunome Completes Dosing First Cohort Of Patients In Phase 1b Study Of IMM-BCP-01
Brief: AbbVie, Immunome Collaborates To Discover Multiple Novel Oncology Targets
Brief: Immunome Reports Q3 Financial Results
Immunome Inc reports results for the quarter ended in September - Earnings Summary
Immunome Inc expected to post a loss of 76 cents a share - Earnings Preview
Brief: Immunome Presents Preclinical Data On Novel Anti-Epn1 Antibody Imm20059
Brief: Immunome Announces Publication In Clinical & Translational Immunology Highlighting B Cell Repertoires In Patients With Breast Cancer
Brief: Immunome Reports Q2 Net Loss Per Share Common Stock of $0.74
Immunome up as antibody cocktail shows promise against Omicron subvariants
Brief: Immunome's Covid-19 Cocktail Retains Neutralizing Activity Against Most Prevalent Omicron Subvariants* In U.S., Ba.4/5 And Ba.2.12.1
Brief: Immunome Announces Initiation Of Phase 1B Study Of Imm-Bcp-01 For The Treatment Of Covid-19
Brief: Immunome Provides Update On Lead Oncology Candidate Targeting IL-38
Brief: Immunome Announces Data Demonstrating Covid-19 Antibody Cocktail Potently Clears Omicron Ba.1 Variant In Hamster Model And Retains Activity Against Ba.2 Subvariant
Immunome Inc reports results for the quarter ended in March - Earnings Summary
Brief: Immunome Reports First Quarter 2022 Financial Results
Immunome Inc expected to post a loss of 69 cents a share - Earnings Preview